Brief: Medicenna Reports Confirmed Partial Response In Pancreatic Cancer And Clinical Update On Mdna11’S Monotherapy Dose Escalation Portion Of The Ongoing Phase 1/2 Ability Study
28/09/2022 14:46
Sept 28 (Reuters) - Medicenna Therapeutics Corp
MDNA.TO :
* MEDICENNA REPORTS CONFIRMED PARTIAL RESPONSE IN PANCREATIC
CANCER AND CLINICAL UPDATE ON MDNA11’S MONOTHERAPY DOSE
ESCALATION PORTION OF THE ONGOING PHASE 1/2 ABILITY STUDY
* MEDICENNA - NEW DATA ON MDNA11'S SAFETY, PHARMACOKINETIC
AND
PHARMACODYNAMIC PROFILES ARE EXPECTED TO BE PRESENTED AT A MAJOR
MEDICAL MEETING IN Q4
Source text for Eikon: ID:nGNX4j5kJX
Further company coverage: MDNA.TO
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Medicenna Therapeutics
See all newsBrief: Medicenna Therapeutics - Announces Two New U.S. Patents And One Allowed U.S. Patent Application
Brief: Medicenna Announces The Finalization Of The Terms Of Its Public Offering Of Securities
Brief: Medicenna Announces The Launch Of A Marketed Public Offering Of Securities
Brief: Medicenna Therapeutics Appoints Dr. Nageatte Ibrahim As Chief Medical Officer
Brief: Medicenna Therapeutics Reports Third Quarter Fiscal 2026 Financial Results